Results 111 to 120 of about 4,911,045 (202)

No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician's Point of View. [PDF]

Neurol Int
Müller T.
europepmc   +1 more source

Neuromodulation therapies in the management of tardive dyskinesia: A scoping review. [PDF]

Indian J Psychiatry
Kololichalil A, Jadeer KM, Ganesh R, Verma R, Patil V.   +4 more
europepmc   +1 more source

Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment-Resistant Schizophrenia Patient. [PDF]

Case Rep Psychiatry
Günay U, Demiröz C, Kocaayan FS, Dalkıran İ, Tatlıdil E.   +4 more
europepmc   +1 more source

Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia. [PDF]

Psychiatry Clin Neurosci
Matsuda Y, Suzuki Y.
europepmc   +1 more source

Levodopa exacerbated tremor in Parkinson's disease. [PDF]

Front Neurol
Baizabal-Carvallo JF, Alonso-Juarez M, Fekete R.   +2 more
europepmc   +1 more source

Acute Onset Extrapyramidal Symptoms With Clozapine: A Report of a Rare Case. [PDF]

Cureus
Nandakumar S, Ramdurg S, Chaukimath S, Kalasagond MB, S G G.   +4 more
europepmc   +1 more source

Amantadine-induced livedo reticularis. [PDF]

CMAJ
Shima A, Yoshikawa S, Ueda T.
europepmc   +1 more source

Letter: Clonazepam in the treatment of drug-induced dyskinesia. [PDF]

BMJ, 1975
openaire   +2 more sources

Indirect Striatal Projection Neurons Drive a D2 Receptor-Dependent Pathway to Dyskinesia and Dystonia. [PDF]

Mov Disord
Andreoli L, Nyman T, Espa E, Jakobsson J, Elabi OF, Cenci MA.   +5 more
europepmc   +1 more source

Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson's Disease: A 3-Year Longitudinal Cohort Study. [PDF]

Clin Interv Aging
Wang S, Xue T, Ma R, Shi L, Zhu G, Jiang Y, Yang A, Meng F, Zhang J.   +8 more
europepmc   +1 more source